4.5 Article

Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects

期刊

BREAST CANCER RESEARCH AND TREATMENT
卷 126, 期 3, 页码 621-636

出版社

SPRINGER
DOI: 10.1007/s10549-010-0971-3

关键词

Membrane progesterone receptors; Mammary carcinomas; Progesterone receptor isoforms: membrane-initiated steroid signaling; Antiprogestins; Breast cancer treatment; Non-genomic effects; Progestins

类别

资金

  1. ANPCyT [PICT 07-932, PICT 05-38302]
  2. CONICET [PIP 5351]
  3. Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD
  4. UICC
  5. Avon Foundation
  6. Fundacion Sales

向作者/读者索取更多资源

In this article, we demonstrate the expression of functional progesterone binding sites at the cell membrane in murine mammary carcinomas that are stimulated by progestins and inhibited by antiprogestins. Using confocal immunofluorescence, ligand binding and cell compartment-specific western blots, we were able to identify the presence of the classical progesterone receptors. Medroxyprogesterone acetate (MPA) and RU-486 (1 x 10(-11) and 1 x 10(-8) M) behaved as agonists activating extracellular signal-regulated kinases (ERKs) and progestin-regulated proteins, except for Cyclin D1 and Tissue factor which failed to increase with 1 x 10(-8) M RU-486, an experimental condition that allows PR to bind DNA. These results predicted a full agonist effect at low concentrations of RU-486. Accordingly, at concentrations lower than 1 x 10(-11) M, RU-486 increased cell proliferation in vitro. This effect was abolished by incubation with the ERK kinase inhibitor PD 98059 or by OH-tamoxifen. In vivo, at a daily dose of 1.2 mu g/kg body weight RU-486 increased tumor growth, whereas at 12 mg/kg induces tumor regression. Our results indicate that low concentrations of MPA and RU-486 induce similar agonistic non-genomic effects, whereas RU-486 at higher concentrations may inhibit cell proliferation by genomic-induced effects. This suggests that RU-486 should be therapeutically administered at doses high enough to guarantee its genomic inhibitory effect.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据